Continuous 12-lead electrocardiographic ST monitoring and long-term prognosis after successful coronary stenting

Zairis, Michael N.; Manousakis, Stavros J.; Adamopoulou, Evdokia N.; Makrygiannis, Stamatis S.; Glyptis, Markos P.; Beldekos, Demetrios; Patsourakos, Nikolaos G.; Olympios, Christopher D.; Prekates, A.; Foussas, Stefanos

doi:10.1016/j.ahj.2005.06.011

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiac toxicity of capecitabine is as important as its use, as it is commonly and easily used when 5-FU is contraindicated [5]. For example, the incidence of 5-FU-induced cardiac toxicity is reported to be 1.2–18.0%, whereas the incidence of capecitabine-induced cardiac toxicity is yet to be reported [21,22]. …”

Section: Discussionmentioning

confidence: 99%

“…In addition, ECG findings, which are very important for the diagnosis of cardiac diseases, are at the same time very important for the monitoring of the applied treatments. Therefore, changes in ECG findings are paid greater attention [20,21]. 5-FU-induced cardiac toxicity can be easily determined based on the typical ECG findings combined with chest pain, palpitations, nausea and sweating [9].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Electrocardiography Changes in Patients Treated with Capecitabine

Koca

Salman²,

Ünek³

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

Background: We aimed to identify the incidence of cardiac events with capecitabine treatment. Methods: The study included 52 patients (median age 59 years) with cancer treated at our Medical Oncology Clinic between 2009 and 2010. Cardiac events from capecitabine treatment were classified into 4 groups: cardiac symptoms, physical signs, electrocardiography (ECG) findings, and severe adverse cardiac effects. Results: The patients received either single-agent capecitabine or a combination chemotherapy including capecitabine. After initiation of capecitabine, 18 patients (34.6%) had new onset cardiovascular symptoms, 6 (11.5%) had new onset physical signs and 17 (32.6%) had new onset ECG findings. New onset ECG findings included prolonged corrected QT interval (n = 10, 19.2%) and prolonged PR interval (n = 3, 5.8%). Severe adverse capecitabine-induced cardiac side effects were observed in 5.8% of the patients, but none of the patients had myocardial infarction or died. Conclusion: Cardiac events are not rare during capecitebine treatment and patients should be followed closely to avoid cardiac morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%